Tango Therapeutics, Inc.
TNGX
$25.60
-$0.05-0.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 53.81M | 3.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 53.81M | 3.18M |
| Cost of Revenue | 37.20M | 33.53M | 32.10M | 30.82M | 32.81M |
| Gross Profit | -37.20M | -33.53M | -32.10M | 23.00M | -29.63M |
| SG&A Expenses | 22.59M | 15.24M | 9.76M | 8.92M | 11.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.79M | 48.77M | 41.86M | 39.74M | 44.15M |
| Operating Income | -59.79M | -48.77M | -41.86M | 14.07M | -40.97M |
| Income Before Tax | -55.34M | -45.51M | -38.80M | 15.87M | -38.82M |
| Income Tax Expenses | 1.00K | 1.00K | -55.00K | -10.00K | 35.00K |
| Earnings from Continuing Operations | -55.34M | -45.51M | -38.75M | 15.88M | -38.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.34M | -45.51M | -38.75M | 15.88M | -38.85M |
| EBIT | -59.79M | -48.77M | -41.86M | 14.07M | -40.97M |
| EBITDA | -59.36M | -48.31M | -41.39M | 14.63M | -40.34M |
| EPS Basic | -0.37 | -0.32 | -0.29 | 0.14 | -0.35 |
| Normalized Basic EPS | -0.23 | -0.20 | -0.18 | 0.09 | -0.22 |
| EPS Diluted | -0.37 | -0.32 | -0.29 | 0.13 | -0.35 |
| Normalized Diluted EPS | -0.23 | -0.20 | -0.18 | 0.08 | -0.22 |
| Average Basic Shares Outstanding | 149.88M | 143.58M | 131.59M | 110.97M | 110.54M |
| Average Diluted Shares Outstanding | 149.88M | 143.58M | 131.59M | 117.78M | 110.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |